Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
HIV Infection
45%
Endocarditis
30%
Personality Tests
30%
Enneagram
30%
Darunavir
30%
New Advances
30%
Tophaceous Gout
30%
Achilles
30%
Dual-energy X-ray Absorptiometry
30%
Injection Drug Use
30%
Oral Therapy
30%
Home Visiting Program
30%
Raltegravir
30%
Etravirine
30%
Maraviroc
30%
Lupus-like
30%
Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)
30%
Shiga Toxin-producing Escherichia Coli
30%
Atypical Hemolytic Uremic Syndrome (aHUS)
30%
Density Score
30%
Non-emergent
30%
Legionella Pneumonia
30%
Pneumonia Infection
30%
Human Immunodeficiency Virus-positive Patients
30%
Rheumatoid Arthritis
30%
Amniotic Fluid Embolus
30%
Antiretroviral Therapy
30%
Quantitative Ultrasound
26%
AIDS/HIV
24%
Chronic Gout
20%
Gouty Arthritis
20%
Conversational Practice
17%
Adverse Effects
15%
Graduate Medical Education
15%
Oral Drug Therapy
15%
Adverse Effect Profile
15%
Virus-like Particles
15%
Pharmacokinetics
15%
HIV-1 Infection
15%
Protease Inhibitors
15%
Multiple Agents
15%
Viral mutation
15%
Clinical Evidence
15%
Drug Intolerance
15%
New Agents
15%
Chemokine Receptor Antagonists
15%
Resistance Effect
15%
Efavirenz
15%
CCR5-tropic
15%
Extensive Drug Resistance
15%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Adverse Event
61%
Parathyroid hormone[1-34]
60%
Endocarditis
45%
Bacterial Endocarditis
35%
Amphotericin B
30%
Gemella
30%
Dapsone
30%
Heparin
30%
Rhabdomyolysis
30%
Heparin Induced Thrombocytopenia
30%
Combination Drug
30%
Burkitt's Lymphoma
30%
Simvastatin
30%
Daptomycin
30%
Staphylococcus Aureus
30%
Clinical Pharmacy
30%
Dicarbonate
20%
Etravirine
20%
Darunavir
20%
Nonnucleoside Reverse Transcriptase Inhibitor
20%
Maraviroc
20%
Raltegravir
20%
Statin (Protein)
20%
Drug Resistance
20%
Table Salt
20%
Combination Therapy
19%
Human Immunodeficiency Virus Infection
17%
Drug Intolerance
15%
Thrombocyte Factor 4
11%
Histoplasma
9%
Amphotericin B Deoxycholate
9%
Hydration
9%
Ciclosporin
9%
Ezetimibe Plus Simvastatin
9%
Creatine Kinase
9%
Ezetimibe
9%
Maturity Onset Diabetes of the Young
9%
Filobasidiella
9%
Ajellomyces capsulatus
9%
Systemic Mycosis
9%
Antiinfective Agent
9%
Creatinine
9%
Human Immunodeficiency Virus 1 Infection
9%
Integrase Inhibitor
9%
Clinical Pharmacokinetics
9%
Efavirenz
9%
Chemokine Receptor Antagonist
9%
Kidney Failure
9%
Proteinase Inhibitor
9%
Medicine and Dentistry
Health Care Cost
43%
Human Immunodeficiency Virus
30%
Endocarditis
30%
Amnion Fluid Embolism
30%
Aprotinin
30%
Coagulopathy
30%
Drug Use
30%
Lupus Erythematosus
30%
Heparin-Induced Thrombocytopenia
30%
Dual-Energy X-Ray Absorptiometry
30%
Heparin
30%
Primary Health Care
30%
Shiga Toxin Producing Escherichia Coli
30%
Atypical Hemolytic Uremic Syndrome
30%
Nephropathy
30%
Inflammatory Arthritis
30%
Gout
30%
Rheumatoid Arthritis
30%
Embolism
30%
Injection
30%
Oral
30%
Pneumonia
30%
Platelet
24%
Complication of Pregnancy
20%
Cyanosis
19%
HIV-associated Nephropathy
18%
Thrombocyte Factor 4
15%
Bone Density
15%
Nervous System
15%
Outpatient
13%
Glomerulopathy
12%
Antigen Antibody Complex
12%
Glomerulonephritis
12%
Dyspnea
11%
Infective Endocarditis
9%
Fetus Distress
9%
Clinical Feature
9%
Shock (Circulatory)
9%
Cardiopulmonary Arrest
9%
Heparinization
9%
Venous Thromboembolism
9%
Medicaid
9%
Bacterium
9%
Diagnosis
9%
Edema
9%
Disseminated Intravascular Coagulation
9%
Hemorrhagic Hypotension
9%
Assisted Circulation
9%
Maternal Mortality
9%
Mortality Rate
9%
